These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1981623)

  • 41. Electroencephalographic sleep in clinically stable schizophrenic patients: two-weeks versus six-weeks neuroleptic-free.
    Nofzinger EA; van Kammen DP; Gilbertson MW; Gurklis JA; Peters JL
    Biol Psychiatry; 1993 Jun 1-15; 33(11-12):829-35. PubMed ID: 8104041
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased serum IgE in schizophrenic patients who responded poorly to neuroleptic treatment.
    Ramchand R; Wei J; Ramchand CN; Hemmings GP
    Life Sci; 1994; 54(21):1579-84. PubMed ID: 7910931
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The concept of supersensitivity psychosis.
    Kirkpatrick B; Alphs L; Buchanan RW
    J Nerv Ment Dis; 1992 Apr; 180(4):265-70. PubMed ID: 1348269
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.
    Csernansky JG; Kaplan J; Holman CA; Hollister LE
    Psychopharmacology (Berl); 1983; 81(2):115-8. PubMed ID: 6138793
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients.
    Rao ML; Brown WA
    Psychopharmacology (Berl); 1987; 93(2):237-42. PubMed ID: 2892222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
    Faraone SV; Brown WA; Laughren TP
    J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [ERPs changes during neuroleptic treatment in schizophrenia--a vulnerability marker in schizophrenia].
    Asato N; Hirayasu Y; Hiramatsu K; Ohta H
    Seishin Shinkeigaku Zasshi; 1999; 101(3):254-76. PubMed ID: 10375977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prolactin bioassay in schizophrenia before and after neuroleptics.
    Peabody CA; Warner MD; Griffin M; Boutros NN; Worsley IG; Friesen HG
    Psychiatry Res; 1992 Mar; 41(3):249-55. PubMed ID: 1594711
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lymphocyte subsets in schizophrenic disorders. Relationship with clinical, neuromorphological and treatment variables.
    Masserini C; Vita A; Basile R; Morselli R; Boato P; Peruzzi C; Pugnetti L; Ferrante P; Cazzullo CL
    Schizophr Res; 1990; 3(4):269-75. PubMed ID: 1980614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blood biogenic amines during clozapine treatment of early-onset schizophrenia.
    Schulz E; Fleischhaker C; Clement HW; Remschmidt H
    J Neural Transm (Vienna); 1997; 104(10):1077-89. PubMed ID: 9503259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia.
    Tune LE; Creese I; Depaulo JR; Slavney PR; Coyle JT; Snyder SH
    Am J Psychiatry; 1980 Feb; 137(2):187-90. PubMed ID: 6101524
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low serum prolactin and early relapse following neuroleptic withdrawal.
    Brown WA; Laughren T
    Am J Psychiatry; 1981 Feb; 138(2):237-9. PubMed ID: 6109456
    [No Abstract]   [Full Text] [Related]  

  • 54. Low serum neuroleptic levels predict relapse in schizophrenic patients.
    Brown WA; Laughren T; Chisholm E; Williams BW
    Arch Gen Psychiatry; 1982 Sep; 39(9):998-1000. PubMed ID: 6126172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term neuroleptic treatment of chronic schizophrenic patients: clinical and biochemical effects of withdrawal.
    Zander KJ; Fischer B; Zimmer R; Ackenheil M
    Psychopharmacology (Berl); 1981; 73(1):43-7. PubMed ID: 6112769
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of clozapine on biogenic amines within the scope of drug treatment of schizophrenic psychoses in adolescence].
    Schulz E; Remschmidt H; Fleischhaker C
    Z Kinder Jugendpsychiatr; 1994 Dec; 22(4):285-98. PubMed ID: 7856324
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia.
    Magharious W; Goff DC; Amico E
    Psychiatry Res; 1998 Feb; 77(3):159-66. PubMed ID: 9707298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug withdrawal in chronic schizophrenic patients: in search of neuroleptic-induced supersensitivity psychosis.
    Weinberger DR; Bigelow LB; Klein ST; Wyatt RJ
    J Clin Psychopharmacol; 1981 May; 1(3):120-3. PubMed ID: 6117582
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neurological soft signs in neuroleptic-naive and neuroleptic-treated schizophrenic patients and in normal comparison subjects.
    Gupta S; Andreasen NC; Arndt S; Flaum M; Schultz SK; Hubbard WC; Smith M
    Am J Psychiatry; 1995 Feb; 152(2):191-6. PubMed ID: 7840351
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neuroleptic treatment is an unlikely cause of elevated dopamine in thalamus of schizophrenic subjects.
    Oke AF; Putz C; Adams RN; Bird ED
    Psychiatry Res; 1992 Dec; 45(4):203-8. PubMed ID: 1363335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.